JeffreyStevenHumphreyMD

PubMed

• 36 citations
  Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia
  Mary D. Ruppe, Xiaoping Zhang, Erik A. Imel, Thomas Weber, Mark A. Klausner
  Bone Reports. 2016-12-01
• 39 citations
  Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypoph...
  Xiaoping Zhang, Erik A. Imel, Mary D. Ruppe, Thomas Weber, Mark A. Klausner
  Journal of Clinical Pharmacology. 2016-02-01
• 43 citations
  Constitutional von Hippel-Lindau (VHL) gene deletions detected in VHL families by fluorescence in situ hybridization.
  Svetlana Pack, Berton Zbar, Evgenia Pak, David O. Ault, Jeffrey S. Humphrey
  Cancer Research. 1999-11-01

Journal Articles

• Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia  
  Carpenter TO, Imel EA, Ruppe MD, Weber, TJ, Klausner MK, Wooddell MM, Kawakami T, Ito T, Zhang X, Humphrey J, Insogna K, Peacock, J Clin Invest, 1/1/2014
• The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institut...  
  Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Le Blanc M, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D, Clin Cancer Res, 1/15/2010
• GCP Data Quality for Early Clinical Development  
  Rock EP, Molloy VJ, and Humphrey JS, Clin Cancer Res, 1/1/2010
• Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: Nati...  
  Leighl NB, Paz-Ares L, Douillard JY, Peschel C, Arnold A, Depierre A, Santoro A, Betticher DC, Gatzemeier U, Jassem J, Crawford J, Tu D, Bezjak A, Humphrey JS, Voi M,..., JCO, 1/1/2005
• Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung c...  
  Douillard JY, Peschel C, Shepherd F, Paz-Ares L, Arnold A, Davis M, Tonato M, Smylie M, Tu D, Voi M, Humphrey JS, Ottaway J, Young K, Van Vreckem A, and Seymour L, Lung Cancer, 1/1/2004
• A Phase I Study of Oral BMS-275291, a Novel Nonhydroxamate Sheddase-Sparing Matrix Metalloproteinase Inhibitor, in Patients with Advanced or Metastatic Cancer  
  Rizvi NA, Humphrey JS, Ness EA, Johnson MD, Gupta E, Williams K, Daly DJ, Sonnichsen D, Conway D, Marshall J, and Hurwitz H, Clin Cancer Res, 1/1/2004
• Reduction of wound angiogenesis in patients treated with BMS-275291, a broad-spectrum matrix metalloproteinase inhibitor  
  Lockhart AC, Braun RD, Yu D, Ross JR, Dewhirst MW, Humphrey JS, Thompson S, Williams KM, Klitzman B, Yuan F, Grichnik JM, Proia AD, Conway DA, and Hurwitz HI, Clin Cancer Res, 1/1/2003
• Ras Farnesylation inhibitors in lung cancer  
  Tuck D and Humphrey JS, Lung Cancer, 1/1/2000
• Phase I Clinical Trial Design in Cancer Drug Development  
  Eisenhauer EA, O'Dwyer PJ, Christian M, and Humphrey J, JCO, 1/1/2000
• Constitutional von Hippel-Lindau (VHL) Gene Deletions Detected in VHL Families by Fluorescence in Situ Hybridization  
  Pack SD, Zbar B, Pak E, Ault DO, Humphrey JS, Pham T, Hurley K, Weil RJ, Park W-S, Kuzmin I, Stolle C, Glenn G, Liotta LA, Lerman MI, Klausner RD, Linehan WM, and Zhua..., Cancer Res, 1/1/1999
• Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene  
  Stolle C, Glenn G, Zbar B, Humphrey JS, Choyke P, Walther M, Pack S, Hurley K, Andrey C, Klausner RD, and Linehan WM, Human Mutation, 1/1/1998
• Yeast-based assays for the detection and characterization of mutations in BRCA1  
  Monteiro ANA, and Humphrey JS, Breast Disease, 1/1/1998
• Human BRCA1 inhibits growth of yeast: potential utility in diagnostic testing  
  Humphrey JS, Salim A, Erdos M, Brody L, Collins F, and Klausner RD, PNAS, 1/1/1997
• Nuclear/ cytoplasmic localization of the VHL tumor suppressor gene product is determined by cell density  
  Lee S, Chen DY, Humphrey JS, Gnarra J, Linehan MW, and Klausner RD, PNAS, 1/1/1996
• Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations  
  Duan RD, Humphrey JS, Chen DY, Weng Y, Sukegawa J, Lee S, Gnarra JR, Linehan WM, and Klausner RD, PNAS, 1/1/1995
• Molecular Cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma  
  Gnarra JR, Duan DR, Weng Y, Humphrey JS, Chen DYT, Lee S, Pause A, Dudley CF, Latif F, Kuzmin I, Schmidt L, Duh FM, Lerman MI, Zbar B, Klausner RD, and Linehan WM, Biochimica Biophysica Acta, 1/1/1995
• Durable complete remission of macroglobulinemia after splenectomy: A report of two cases and review of the literature  
  Humphrey JS, and Conley CL, Am J Hematology, 1/1/1995
• An acidic sequence within the cytoplasmic domain of furin functions as a determinant of trans-Golgi network localization and internalization from the cell surface  
  Voorhees P, Deignan E, vanDonselaar E, Humphrey JS, Marks MS, Peters PJ, and Bonifacino JS, EMBO J, 1/1/1995
• Acute renal toxicity associated with Suramin in the treatment of prostate cancer  
  Figg WD, Cooper MR, Thibault A, Headlee D, Humphrey JS, Bergan RC, Reed E, and Sartor O, Cancer, 1/1/1994
• TGN38 recycles basolaterally in polarized Madin-Darby canine kidney cells  
  Rajasekaran AK, Humphrey JS, Wagner M, Miesenböck G, LeBivic A, Bonifacino JS, and Rodriguez-Boulan E, Mol Biol Cell, 1/1/1994
• The cytoplasmic domain mediates localization of furin to the trans-Golgi network en route to the endosomal/lysosomal system  
  Bosshart H, Humphrey JS, Deignan E, Davidson J, Drazba J, Yuan L, and Bonifacino JS, J Cell Biol, 1/1/1994
• Localization of TGN38 to the trans-Golgi Network: Involvement of a cytoplasmic tyrosine-containing sequence  
  Humphrey JS, Peters PJ, Yuan LC, and Bonifacino JS, J Cell Biol, 1/1/1993
• Matrix metalloproteinase inhibitors in lung cancer  
  Humphrey JS, Lung Cancer
• Join now to see all

Books/Book Chapters

• Development of Anti-Angiogenic Agents 
  Chapter: BMS-275291, a Novel, Sheddase-sparing Matrix Metalloproteinase Inhibitor. 
  Humphrey JS, Naglich J, Gupta E and Sonnichsen DEditors: Beverly Teicher.2002
• Cancer Treatment and Research 
  Chapter: Von Hippel-Lindau syndrome: Hereditary cancer arising from inherited mutations of the VHL tumor suppressor gene. 
  Humphrey JS, Klausner RD, and Linehan WM1996

Abstracts/Posters

• Carpenter. The First Multi-Dose Trial of a Human Anti-FGF23 (Fibroblast Growth Factor 23) Antibody (KRN23) in Adults with X-Linked Hypophosphatemia (XLH).
  Erik A. Imel, Xiaoping Zhang, Mary D. Ruppe, Thomas J. Weber, Mark A. Klausner, Takahiro Ito, Maria Vergeire, Jeffrey Humphrey, Francis H. Glorieux, Anthony A. Portale..., 2014 ICE/ENDO (16th International congress of Endocrinology/The Endocrine Society's 96th Annual Meeting and Expo), Chicago, IL, 1/21/2014
• Carpenter. Pharmacokinetics (PK) and Pharmacodynamics (PD) Following Four Monthly Doses of a Human Monoclonal Anti-FGF23 (Fibroblast Growth Factor 23) Antibody (KRN23)...
  Xiaoping Zhang, Erik A. Imel, , Mary D. Ruppe, Thomas J. Weber, Mark A. Klausner, Takahiro Ito, Maria Vergeire, Jeffrey Humphrey, Francis H. Glorieux, Anthony A. Porta..., 2014 ICE/ENDO (16th International congress of Endocrinology/The Endocrine Society's 96th Annual Meeting and Expo), Chicago, IL, 1/21/2014
• fect of Four Monthly Doses of a Human Monoclonal Anti-FGF23 (Fibroblast Growth Factor 23) Antibody (KRN23) on Quality of Life in X-linked Hypophosphatemia (XLH).
  Mary D. Ruppe1, Xiaoping Zhang, Erik A. Imel, Thomas J. Weber, Mark A. Klausner, Takahiro Ito, Maria Vergeire, Jeffrey Humphrey, Francis H. Glorieux, Anthony A. Porta..., 2014 ICE/ENDO (16th International congress of Endocrinology/The Endocrine Society's 96th Annual Meeting and Expo), Chicago, IL, 1/21/2014
• A Randomized, Double-blind, Placebo-Controlled, Ascending, Single-Dose Study of a Human Monoclonal Anti-FGF23 Antibody (KRN23) in X-linked Hypophosphatemia. Poster and...
  Carpenter TO, Imel EA, Ruppe MD, Weber, TJ, Klausner MK, Wooddell MM, Kawakami T, Ito T, Zhang X, Humphrey J, Insogna K, Peacock, 41st European Calcified Tissue Society Congress (ECTS), Bone Abstracts, Prague, Czech Republic, 1/17/2014
• Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Human Monoclonal Anti-FGF23 Antibody (KRN23) after Ascending Single-Dose Administration in Patients with X-linked ...
  Zhang X, Carpenter TO, Imel EA, Ruppe MD, Weber, TJ, Klausner MK, Wooddell MM, Kawakami T, Ito T, Humphrey J, Insogna K, Peacock, 41st European Calcified Tissue Society Congress (ECTS), Bone Abstracts, Prague, Czech Republic, 1/17/2014
• A First-In-Human, Randomized, Double-blind, Placebo-Controlled, Single-Dose Study of a Human Monoclonal Anti-FGF23 Antibody (KRN23) in X-linked Hypophosphatemia.
  Carpenter TO, Imel EA, Ruppe MD, Weber, TJ, Klausner MK, Wooddell MM, Kawakami T, Ito T, Zhang X, Humphrey J, Insogna K, Peacock, ASBMR 2013 Annual Meeting, J Bone Miner Res, Baltimore Convention Center, Baltimore, MD, 1/4/2013
• Pharmacokinetics and Pharmacodynamics of a Human Monoclonal Anti-FGF23 Antibody (KRN23) after Single-Dose Administration to Patients with X-linked Hypophosphatemia.
  Zhang X, Carpenter TO, Imel EA, Ruppe MD, Weber, TJ, Klausner MK, Wooddell MM, Kawakami T, Ito T, Humphrey J, Insogna K, Peacock, ASBMR 2013 Annual Meeting, J Bone Miner Res, Baltimore Convention Center, Baltimore, MD, 1/4/2013
• Value of Survival Gains In Chronic Myelogenous Leukemia.
  Yin W,Penrod JR,Maclean R, Humphrey JS, Bahceci E, Lakdawalla D, Blood (ASH Annual Meeting Abstracts), 1/1/2010
• The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Long-term outcomes in first-line patients (pts).
  C. W. Ryan, R. M. Bukowski, R. A. Figlin, J. J. Knox, T. E. Hutson, J. P. Dutcher, J. George, J. Kirshner, J. Humphrey, W. M. Stadler, ASCO Annual Meeting Proceedings, Journal of Clinical Oncology, 1/1/2007
• Randomized Phase II Study of BMS-275291 versus Placebo in Patients with Stage IIIB or IV Non-small Cell Lung Cancer Receiving Paclitaxel + Carboplatin: National Cancer...
  Douillard JY, Petersen V, Shepherd F, Paz-Ares L, Arnold A, Tonato M, Davis M, Smylie M, Van Vreckem A, Humphrey JS, Ottawary J, and Seymour L, European Conference on Clinical Oncology, 1/1/2001
• Join now to see all

Lectures

• Nexavar (R) and Bayer Pipeline 
  Multiple Locations, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015 - 1/1/2015
• Accelerating Anticancer Agent Development and Validation Workshop 
  1/1/2012
• Best Practices in Oncology Clinical Development Panel 
  Philadelphia, PA - 1/1/2008
• Nexavar (R) development - Placing patients firs 
  1/1/2007
• Nexavar (R) hepatocellular carcinoma data 
  1/1/2007
• Nexavar (R) breast cancer data 
  1/1/2006
• Nexavar (R) lung cancer data 
  1/1/2006
• Antisense Oligonucleotides/ Experimental Drugs in Myeloma 
  New York, NY - 1/1/2003
• EGF and VEGF receptors 
  New York, NY - 1/1/2003
• Clinical Trials for Anti-angiogenic Therapy of Cancer 
  1/1/2001
• Maximizing potential of anti-angiogenic agent 
  New York, NY - 1/1/2000
• Anti-angiogenic agents 
  Washington, DC - 1/1/2000
• Matrix Metalloprotease Development 
  Marbella, Spain - 1/1/2000
• BMS Pipeline 
  Duke University Medical Center - 1/1/2000
• Join now to see all